WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Stemcentrx, Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Innatoss Laboratories | September 15, 2020
Innatoss Laboratories announced today the first neutralizing antibody testing service against SARS-CoV-2 for the public in Europe, using GenScript's cPass ™ SARS-CoV-2 Neutralization Antibody Detection Kit. The kit is the first in the world that enables rapid detection of neutralizing antibodies (NAbs), the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection. Innatoss is the first medical lab in Europe to provide a service...
CELL AND GENE THERAPY
Biocytogen | September 16, 2022
Biocytogen Pharmaceuticals Co., Ltd. announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform. Biocytogen’s TCR-mimic antibody development platform utilizes its pro...
INDUSTRIAL IMPACT, MEDICAL
biotechnology news | December 22, 2022
Enveda Biosciences announced that it has closed a $68-million equity and debt financing. Dimension led the Series B round, which included participation by multiple new institutional investors, including FPV, Jazz Venture Partners, Level Ventures, Amino Collective, Allen & Co, and Possible Ventures. All of Enveda’s current major investors, including True Ventures, Lux Capital, Wireframe Ventures, Hummingbird Ventures, and Two Sigma Ventures, also participated in the round. ...
MEDTECH, INDUSTRIAL IMPACT
Generate Biomedicines | December 07, 2022
Generate Biomedicines announced that Dimitris Agrafiotis, Ph.D., FRSC, has been appointed Chief Digital Officer. He will lead multidisciplinary teams across technology, data science, automation, and digital transformation to support the rapid growth of the machine learning-powered biotech. Dr. Agrafiotis brings deep expertise at the intersection of digital technology, data science, and life sciences spanning the entire R&D continuum across venture-funded biotech, big pharma, a...
RESEARCH
Whitepaper
MEDICAL
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE